Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical Business ReviewJascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Business Review Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Respiratory Read full story Post navigation Previous: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPFNext: Regeneron immunotherapy combo comes up short in melanoma trial Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026